Inspira™ and Ennocure In Vitro Study Results Show 100% Prevention of Bacterial Growth that Causes Bloodstream Infections

Rhea-AI Summary

Inspira Technologies and Ennocure MedTech announce successful results in developing a bio-electronic treatment to prevent bloodstream infections, showing a 75% reduction in bacterial growth within 4 hours and 100% reduction within 24 hours. The technology aims to inhibit bacterial proliferation without the use of antiseptic agents, potentially offering advantages over current standard care solutions.

Insights

Medical Research Analyst

The study results from Inspira and Ennocure's collaboration indicating a significant reduction in bacterial growth post-treatment present a promising advancement in infection control within intensive care units. The ability to integrate bio-electronic technology into existing patient treatment systems like the INSPIRA ART could represent a paradigm shift in managing hospital-acquired infections, which are a major concern for healthcare providers.

Reducing reliance on antiseptic agents not only circumvents the issue of bacterial resistance but also minimizes potential side effects like allergies. This could lead to improved patient outcomes and potentially reduce the length of hospital stays, thereby decreasing healthcare costs. However, the transition from in vitro to in vivo and eventually to human trials, is fraught with challenges. The efficacy and safety profiles will need to be robust to gain regulatory approval and market acceptance.

From an investment perspective, the development of this technology could open up new market opportunities for Inspira, potentially increasing its market share and providing a competitive edge. However, investors should monitor the progression of clinical trials and regulatory hurdles, as these will be critical in determining the technology's commercial viability.

Healthcare Industry Analyst

The announcement showcases a significant leap in the field of medical technology, particularly in the fight against nosocomial infections. The healthcare industry is constantly in search of innovative solutions to reduce infection rates, which are a key performance indicator for hospitals and healthcare facilities. The technology's potential to prevent bacterial growth without the use of chemicals could be a game-changer, aligning with the industry's move towards reducing antibiotic usage and preventing antimicrobial resistance.

Long-term, the adoption of such technologies could lead to a shift in hospital infection control protocols, possibly influencing the strategies of other medical technology firms. Companies that fail to innovate in this direction might find themselves at a competitive disadvantage. For investors, the technology's progress could signal a long-term growth trajectory for Inspira, contingent on successful clinical trials and adoption by healthcare providers.

Biotech Patent Attorney

The proprietary nature of the bio-electronic treatment being developed by Inspira and Ennocure suggests a strategic move to secure intellectual property rights that could be critical in establishing a unique market position. The ability to patent novel medical technologies can provide a company with a temporary monopoly, allowing for the recoupment of R&D investments and potentially high-profit margins.

For stakeholders, the protection of this technology through patents could safeguard against competition, ensuring that Inspira and Ennocure maintain market exclusivity for a period. However, the complexity of patent law in biotechnology, especially for such novel treatments, requires careful navigation to avoid infringement issues and to ensure the patent's enforceability. Stakeholders should consider the strength of the companies' patent strategy and its potential impact on market entry barriers for competitors.

RA'ANANA, Israel, April 10, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira"), a breakthrough medical technology company, together with Ennocure MedTech Ltd. ("Ennocure"), announced results from their collaborative development of a proprietary bio-electronic treatment to prevent associated bloodstream infections in patients in intensive care units.

Once developed, Inspira plans to integrate the bio-electronic novel physical stimulation technology, into the INSPIRA™ ART patient treatment.

The results of the in vitro study showed a 75% reduction in bacterial growth 4 hours after the application of the treatment and a 100% reduction within 24 hours. The in vitro study was carried out at the Hebrew University of Jerusalem and involved testing bioelectric patches in an in vitro environment. As part of the in vitro study, bacteria were cultured and spread on agar in petri dishes. The bioelectric patch was then applied to the agar plate and activated for a pre-specified duration. Following the procedure, the agar plates were transferred to an incubation chamber for 24 hours and thereafter examined.

This technology is based on the use of electrical pulses that inhibit bacterial proliferation. This technology may prevent bacteria from multiplying and spreading by physical means, a solution that does not require antiseptic and disinfectant agents. This technology may have certain advantages, including as a potential effective mitigation solution to certain side effects in current standard care solutions that use antiseptic agents and materials, such as allergies. These standard care solutions may also encounter bacterial resistance and limited efficacy.

The next major research and development milestone in our collaboration with Ennocure involves conducting tests on an ex vivo model to evaluate the efficacy of the treatment in anticipation of the first prospective first-in-human trials.

Dagi-Ben Noon, CEO of Inspira, stated: "By integrating our technology to adaptatively oxygenate blood directly with Ennocure's infection prevention solutions, we are potentially further expanding the benefits of the INSPIRA ART."

Dr. Manuela Hod, CEO of Ennocure, stated: "Our team is positive that these results show potential applicability of this technology to combat life-threatening infections."

About Ennocure MedTech Ltd.

Ennocure, is a pioneer in the development of bio-electronic wound dressing. At the core of the technology is a proprietary bio-electronic wound dressing designed to prevent bacterial infections, while providing remote wound monitoring & infection alerts based on AI-driven therapy.

About Inspira Technologies OXY B.H.N. Ltd.

Inspira™ Technologies is an innovative medical technology company in the respiratory treatment arena. The Company has developed a breakthrough Augmented Respiration Technology (INSPIRA ART), designed to rebalance patient oxygen saturation levels. This technology potentially allows patients to remain awake during treatment while reducing the need for highly invasive, risky, and costly mechanical ventilation systems that require intubation and medically induced coma. The Company's products have not yet been tested or used in humans and has not been approved by any regulatory entity.

For more information, please visit our corporate website: https://inspira-technologies.com

Forward-Looking Statement Disclaimer

This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses the potential benefits of the Company's products and potential products, the potential advantages of the bio-electronic treatment, that if developed, the Company plans to integrate the bio-electronic physical stimulation technology into the INSPIRA™ ART treatment, that following its next milestone in its collaboration with Ennocure it hopes that it would gain authorization to conduct in-human clinical trials and that it is potentially further expanding the benefits of the INSPIRA ART. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2023 filed with the U.S. Securities and Exchange Commission (the "SEC"), which is available on the SEC's website, http://www.sec.gov

For more details:
Public Relations Manager
Adi Shmueli
Inspira Technologies
info@inspirao2.com
+972-9-9664485

Copyright © 2018-2024 Inspira Technologies OXY B.H.N. LTD., All rights reserved.

Logo: https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg

 

View original content:https://www.prnewswire.com/news-releases/inspira-and-ennocure-in-vitro-study-results-show-100-prevention-of-bacterial-growth-that-causes-bloodstream-infections-302113107.html

SOURCE Inspira Technologies

FAQ

What are the results of the in vitro study on Inspira Technologies' bio-electronic treatment?

The in vitro study showed a 75% reduction in bacterial growth 4 hours after treatment and a 100% reduction within 24 hours.

How does the bio-electronic treatment developed by Inspira Technologies work?

The technology uses electrical pulses to inhibit bacterial proliferation without the need for antiseptic agents, potentially offering advantages over current standard care solutions.

What is the next research and development milestone for Inspira Technologies and Ennocure MedTech collaboration?

The next milestone involves conducting tests on an ex vivo model to evaluate the treatment's efficacy in anticipation of the first prospective first-in-human trials.

Who are the CEOs of Inspira Technologies and Ennocure MedTech?

Dagi-Ben Noon is the CEO of Inspira Technologies, and Dr. Manuela Hod is the CEO of Ennocure MedTech.